# A Study to Investigate the Safety, Tolerability and Pharmacokinetics of OZ439 in Healthy Male and Female Subjects

> **NCT00928083** · PHASE1 · COMPLETED · sponsor: **Medicines for Malaria Venture** · enrollment: 63 (actual)

## Conditions studied

- Malaria Falciparum
- Malaria Vivax
- Healthy Volunteers

## Interventions

- **DRUG:** OZ439 50mg API capsules
- **DRUG:** OZ439 200mg API capsules
- **DRUG:** OZ439 400mg aqueous dispersion
- **DRUG:** OZ439 800mg aqueous dispersion
- **DRUG:** OZ439 100mg API capsules
- **DRUG:** OZ439 400mg API capsules
- **DRUG:** OZ439 1600mg aqueous dispersion
- **DRUG:** OZ439 800mg API capsules
- **DRUG:** OZ439 1200mg API capsules
- **DRUG:** Placebo
- **DRUG:** OZ439 200mg aqueous dispersion

## Key facts

- **NCT ID:** NCT00928083
- **Lead sponsor:** Medicines for Malaria Venture
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04
- **Primary completion:** 2009-10
- **Final completion:** 2009-12
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2015-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00928083

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00928083, "A Study to Investigate the Safety, Tolerability and Pharmacokinetics of OZ439 in Healthy Male and Female Subjects". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00928083. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*